Table 4.
Difference in proportion of patients who achieve global assessment and investigator global assessment of success (ratings of ‘excellent’ or ‘good’)
| Age group (years) | Fentanyl ITS [n/N (%)] | Difference in proportion (95% CI) | p valuea |
|---|---|---|---|
| Patient global assessment | |||
| <65 | 731/890 (82.1) | ||
| 65–74 | 207/247 (83.8) | −1.671 (−7.016 to 3.674) | 0.5398 |
| 75–84 | 103/122 (84.4) | −2.291 (−9.466 to 4.884) | 0.5311 |
| ≥85 | 10/12 (83.3) | −1.199 (−22.797 to 20.400) | 0.9133 |
| Investigator global assessment | |||
| <65 | 763/890 (85.7) | ||
| 65–74 | 220/247 (89.1) | −3.338 (−8.091 to 1.414) | 0.1684 |
| 75–84 | 112/122 (91.8) | −6.073 (−12.453 to 0.307) | 0.0621 |
| ≥85 | 10/12 (83.3) | 2.397 (−16.809 to −21.603) | 0.8066 |
95% CIs and p-values were based on the mixed model
CI confidence interval, ITS iontophoretic transdermal system
aThe comparison is between each age group and the <65 years group